Highlights GB Sciences, Inc.

Equities

GBLX

US3615441090

Market Closed - OTC Markets Other stock markets 20:54:33 03/06/2024 BST			5-day change	1st Jan Change
0.0112 ^USD	-10.40%		-5.08%	+75.00%

02-12	GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-20	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	14/07/23	CI
Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of Lethbridge	11/07/23	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	03/02/23	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	09/11/22	CI
Gb Sciences, Inc. Receives Positive Preclinical Results in an Interim Report from Its Study Using Preclinical Zebrafish Models of Stress At the National Research Council of Canada	24/10/22	CI
GB Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22	CI
GB Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	30/06/22	CI
Gb Sciences, Inc. Showcases Its Pharos™ Drug Discovery Platform At the 2Nd Alcor Drug Discovery Platform Summit	12/05/22	CI
GB Sciences, Inc. to Begin Dosage Study for its Novel Parkinson's Disease Formulations at the University of Lethbridge	12/04/22	CI
Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research Article	29/03/22	CI
GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis	01/03/22	CI
GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/02/22	CI
An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. for $8 million.	10/01/22	CI
Gb Sciences Reports Positive Results from Study of its Potential Treatment for Cytokine Release Syndrome	06/12/21	CI
GB Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	15/11/21	CI
GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation	14/09/21	CI
Gb Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2021	06/07/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GB Sciences, Inc.

Equities

GBLX

US3615441090

Highlights

Filters